Harnessing PROTAC technology to combat stress hormone receptor activation

Abstract excerpt

Counteracting the overactivation of glucocorticoid receptors (GR) is an important therapeutic goal in stress-related psychiatry and beyond. The only clinically approved GR antagonist lacks selectivity and induces unwanted side effects. To complement existing tools of small-molecule-based inhibitors, we present a highly potent, catalytically-driven GR degrader, KH-103, based on proteolysis-targeting chimera...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Neuroblastoma Research and Treatments
• Share to Protein Degradation and Inhibitors
• Share to Ubiquitin and proteasome pathways